Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

ed net loss per common share for the six

months ended June 30, 2008 and 2007, respectively. Research and

development expense and general and administrative expense includes

$623 and $706 of non-cash operating expenses determined in accordance

with SFAS No. 123R for the six months ended June 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

June 30, December 31,

2008 2007

(Unaudited) (Audited)

Assets

Cash, cash equivalents and securities

available-for-sale $ 42,112 $ 56,495

Other current assets 1,276 1,004

Noncurrent assets 3,560 4,027

Total assets $ 46,948 $ 61,526

Liabilities and Stockholders' Equity

Current liabilities $ 4,140 $ 5,415

Other long-term liabilities 124 432

Stockholders' equity 42,684 55,679

Total liabilities and

stockholders' equity $ 46,948 $ 61,526


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... The Regulatory Affairs Professionals Society ... offices in Asia—one in Singapore and one in Shanghai, ... RAPS’ Pan-Asia office , serving the Asia Pacific region, ... audiences within China. , The announcement comes just a ... Singapore government agencies to develop and implement a new ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s finest agricultural ... Teachers Ambassador Academy this week (NATAA) at the company’s ... , The NATAA “Ag Academy” is a professional development ... of the National FFA Foundation and the ... The highly recommended agriscience teachers, who are participating in ...
(Date:6/18/2013)... 2013 The Pistoia Alliance ... HELM biomolecular representation standard software toolkit and editor ... HELM (Hierarchical Editing Language for Macromolecules) enables ... (e.g. proteins, nucleotides, antibody drug conjugates) whose size ... methodologies impractical or unusable. HELM solves this problem ...
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
Breaking Biology Technology:RAPS Opens Offices in Singapore and China 2RAPS Opens Offices in Singapore and China 3DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2
... September 1, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Deloitte Recap recently presented the Allicense 2010 ... biotechnology firm, Exelixis, in recognition of their potential ... worldwide exclusive licenses for two early-stage cancer treatments ... inhibitor programs.  In exchange, Sanofi-aventis provided Exelixis an ...
... Rx, the developers of PharmFilm® technology and a ... today announced that its partner, Reckitt Benckiser Pharmaceuticals ... plc (LSE: RB), has received approval from the ... Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for ...
Cached Biology Technology:Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer 2MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence 2MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence 3
(Date:6/17/2013)... 2013 An international team led by scientists at ... Institute and Albert Einstein College of Medicine of Yeshiva ... that attacks the tuberculosis (TB) bacterium in two different ... solve one of the major global health crises of ... strains," said Peter G. Schultz, the Scripps Family Chair ...
(Date:6/17/2013)... ST. LOUIS -- In research published in Biochemical ... describe a technology that can detect new, previously unknown ... for viruses even when doctors have not identified a ... , In the new approach, scientists use ... discover viruses. , Taking advantage of the complete deciphering ...
(Date:6/17/2013)... early onset of puberty in girls, a new clinical ... Endocrine Society,s 95th Annual Meeting in San Francisco. , ... 10 and 14. Boys undergo these changes later, usually ... is diagnosed in girls when sexual development begins before ... when these changes occur before age 9. , Recently, ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Vitamin D supplementation may delay precocious puberty in girls 2
... to examine the role of sweeteners in the ... among various ingredients used in scientific studies, ,according ... distinctly different ingredients, such ,as pure fructose and ... and misleads ,consumers. Recent studies using ...
... Ben-Gurion University of the Negev engineers have developed ... reactors, making it unsuitable for use in nuclear arms. ... the basic synthetic element found in commercial smoke detectors ... peaceful purposes. , This technique could help "de-claw" more ...
... similar, if not lower, costs and very large reductions ... one of the key take-home messages from a series ... America,s Energy Future (RBAEF)" in a special issue of ... journal believes that the collection, which includes a comparative ...
Cached Biology News:Pure fructose frequently confused with high fructose corn syrup 2Ben-Gurion University engineers develop technique to help combat nuclear proliferation 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: